mirror of
https://github.com/msberends/AMR.git
synced 2026-07-12 22:30:55 +02:00
Built site for AMR@3.0.1.9084: 9237bfb
This commit is contained in:
36
llms.txt
36
llms.txt
@@ -48,7 +48,7 @@ in scientific research.
|
||||
|
||||
After installing this package, R knows [**~97 000 distinct microbial
|
||||
species**](https://amr-for-r.org/reference/microorganisms.md) (updated
|
||||
mei 2026) and all [**~620 antimicrobial and antiviral
|
||||
May 2026) and all [**~620 antimicrobial and antiviral
|
||||
drugs**](https://amr-for-r.org/reference/antimicrobials.md) by name and
|
||||
code (including ATC, EARS-Net, ASIARS-Net, PubChem, LOINC and SNOMED
|
||||
CT), and knows all about valid SIR and MIC values. The integral clinical
|
||||
@@ -114,13 +114,11 @@ example_isolates %>%
|
||||
#> ℹ Using column mo as input for `mo_fullname()`
|
||||
#> ℹ Using column mo as input for `mo_is_gram_negative()`
|
||||
#> ℹ Using column mo as input for `mo_is_intrinsic_resistant()`
|
||||
#> ℹ Determining intrinsic resistance based on 'EUCAST Expected
|
||||
#> Resistant Phenotypes' v1.2 (2023). This note will be shown
|
||||
#> once per session.
|
||||
#> ℹ For `aminoglycosides()` using columns GEN (gentamicin), TOB
|
||||
#> (tobramycin), AMK (amikacin), and KAN (kanamycin)
|
||||
#> ℹ For `carbapenems()` using columns IPM (imipenem) and MEM
|
||||
#> (meropenem)
|
||||
#> ℹ Determining intrinsic resistance based on 'EUCAST Expected Resistant Phenotypes' v1.2 (2023).
|
||||
#> This note will be shown once per session.
|
||||
#> ℹ For `aminoglycosides()` using columns GEN (gentamicin), TOB (tobramycin), AMK (amikacin), and KAN
|
||||
#> (kanamycin)
|
||||
#> ℹ For `carbapenems()` using columns IPM (imipenem) and MEM (meropenem)
|
||||
#> # A tibble: 35 × 7
|
||||
#> bacteria GEN TOB AMK KAN IPM MEM
|
||||
#> <chr> <sir> <sir> <sir> <sir> <sir> <sir>
|
||||
@@ -179,7 +177,7 @@ wisca(example_isolates,
|
||||
|
||||
| Piperacillin/tazobactam | Piperacillin/tazobactam + Gentamicin | Piperacillin/tazobactam + Tobramycin |
|
||||
|:---|:---|:---|
|
||||
| 70.1% (65.1-75.4%) | 93.6% (92.1-95%) | 89.8% (87.3-92.4%) |
|
||||
| 70% (64.8-75.2%) | 93.6% (92-95.1%) | 89.9% (87.1-92.5%) |
|
||||
|
||||
WISCA supports stratification by any clinical variable, so you can
|
||||
generate syndrome-specific or ward-specific coverage estimates:
|
||||
@@ -195,9 +193,9 @@ wisca(example_isolates,
|
||||
|
||||
| Syndromic Group | Piperacillin/tazobactam | Piperacillin/tazobactam + Gentamicin | Piperacillin/tazobactam + Tobramycin |
|
||||
|:---|:---|:---|:---|
|
||||
| Clinical | 74.4% (68.2-79.9%) | 93.6% (91.9-95.1%) | 90.4% (86.9-93.3%) |
|
||||
| ICU | 57% (48.6-65.9%) | 86.8% (83.4-89.8%) | 82.9% (77.5-87.1%) |
|
||||
| Outpatient | 57.5% (45.9-69.3%) | 76.6% (70.6-82.3%) | 67.9% (57.6-77.2%) |
|
||||
| Clinical | 74.6% (69.3-80.3%) | 93.6% (92.1-95%) | 90.4% (87-93.2%) |
|
||||
| ICU | 56.9% (48.2-66.3%) | 86.7% (83.4-89.7%) | 82.9% (78.1-87.3%) |
|
||||
| Outpatient | 57.3% (45.8-69.1%) | 76.6% (70.6-81.9%) | 67.9% (58-76.9%) |
|
||||
|
||||
**For AMR surveillance**, traditional antibiograms remain the right tool
|
||||
for tracking resistance per species over time:
|
||||
@@ -207,8 +205,7 @@ for tracking resistance per species over time:
|
||||
antibiogram(example_isolates,
|
||||
mo_transform = "gramstain",
|
||||
antimicrobials = c("AMC", carbapenems(), "TZP"))
|
||||
#> ℹ For `carbapenems()` using columns IPM (imipenem) and MEM
|
||||
#> (meropenem)
|
||||
#> ℹ For `carbapenems()` using columns IPM (imipenem) and MEM (meropenem)
|
||||
```
|
||||
|
||||
| Pathogen | Amoxicillin/clavulanic acid | Imipenem | Meropenem | Piperacillin/tazobactam |
|
||||
@@ -329,16 +326,15 @@ out <- example_isolates %>%
|
||||
# calculate AMR using resistance(), over all aminoglycosides and polymyxins:
|
||||
summarise(across(c(aminoglycosides(), polymyxins()),
|
||||
resistance))
|
||||
#> ℹ For `aminoglycosides()` using columns GEN (gentamicin), TOB
|
||||
#> (tobramycin), AMK (amikacin), and KAN (kanamycin)
|
||||
#> ℹ For `aminoglycosides()` using columns GEN (gentamicin), TOB (tobramycin), AMK (amikacin), and KAN
|
||||
#> (kanamycin)
|
||||
#> ℹ For `polymyxins()` using column COL (colistin)
|
||||
#> Warning: There was 1 warning in `summarise()`.
|
||||
#> ℹ In argument: `across(c(aminoglycosides(), polymyxins()),
|
||||
#> resistance)`.
|
||||
#> ℹ In argument: `across(c(aminoglycosides(), polymyxins()), resistance)`.
|
||||
#> ℹ In group 3: `ward = "Outpatient"`.
|
||||
#> Caused by warning:
|
||||
#> ! Introducing NA: only 23 results available for KAN in group:
|
||||
#> ward = "Outpatient" (whilst `minimum = 30`).
|
||||
#> ! Introducing NA: only 23 results available for KAN in group: ward = "Outpatient" (whilst `minimum =
|
||||
#> 30`).
|
||||
out
|
||||
#> # A tibble: 3 × 6
|
||||
#> ward GEN TOB AMK KAN COL
|
||||
|
||||
Reference in New Issue
Block a user